This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lieff Cabraser Reminds Elan Corporation, Plc Investors Of Upcoming Deadline In Class Action Lawsuits

Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the February 5, 2013 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of persons who purchased or otherwise acquired the American Depositary Shares (“ADRs”), call options, and/or sold the put options of Elan Corporation, plc (“Elan”) (NYSE: ELN) between July 21, 2008 and 4:00 pm EDT on July 29, 2008 (“Class Period”).

If you purchased or otherwise acquired the ADRs, call options, and/or sold the put options of Elan during the Class Period, you may move the Court for appointment as lead plaintiff by no later than February 19, 2013. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Elan investors who wish to learn more about the actions and how to seek appointment as lead plaintiff should click here or contact Sharon Lee of Lieff Cabraser toll-free at (800) 541-7358.

The actions allege that, during the Class Period, S.A.C. Capital Advisors, L.P. (“SAC”), CR Intrinsic Investors (“CRII”), a wholly-owned subsidiary of SAC, and other related parties, including SAC founder and CEO, Steven Cohen, engaged in illegal insider trading in violation of the Securities Exchange Act of 1934 by selling Elan ADRs and trading options prior to the disclosure of adverse clinical trial results for an Alzheimer’s disease drug that was central to Elan’s drug development efforts. Defendants received over $220 million in illegal profits and avoided significant losses by trading on material non-public information.

According to the complaints, a portfolio manager at CRII, Mathew Martoma, received inside information from the doctor who chaired the drug’s safety monitoring committee, Sidney Gilman. The complaints allege that Martoma subsequently shared this information with Cohen, and over the following seven trading days, SAC and Martoma liquidated their entire holdings of Elan ADRs, worth over $365 million, acquired short positions in Elan, and eventually sold over $500 million in Elan securities before the disclosure of adverse results from the clinical trial.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs